Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.

ABSTRACT:

Background and objectives

Serum neurofilament light (sNfL) is a biomarker for neuro-axonal damage in multiple sclerosis (MS). Clinical implementation remains limited. We investigated the impact of implementation on clinical decisions using questionnaires at the MS Center Amsterdam, a tertiary outpatient clinic.

Methods

sNfL assessments were added to routine clinical practice (August 2021-December 2022). Before and after the results, clinicians filled in questionnaires on context of testing, clinical decisions, certainty herein, expectation of magnetic resonance imaging (MRI) activity, urgency, and motivation to receive the sNfL result and perceived value of sNfL.

Results

sNfL was assessed in 166 cases (age 41 ± 12 years, 68% female, 64% disease-modifying therapy (DMT)

SUBMITTER: van Lierop ZY 

PROVIDER: S-EPMC11568682 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature